SynCore Biotechnology
4192:TTTaipei, Taiwan· Est.
Taiwan‑based public biotech advancing oncology, ophthalmology and dermatology pipelines with Phase‑3 assets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Taiwan‑based public biotech advancing oncology, ophthalmology and dermatology pipelines with Phase‑3 assets.
OncologyOphthalmologyDermatology
Technology Platform
Small‑molecule anti‑angiogenesis and targeted biologics platform combined with diagnostic imaging technology for ophthalmic diseases.
Opportunities
Late‑stage oncology assets (SB05) nearing potential approval and a diversified ophthalmic diagnostic portfolio provide multiple pathways to first commercial revenue.
Risk Factors
Clinical trial outcomes, regulatory approvals, and competition from larger oncology biotech firms could delay or limit commercial success.
Competitive Landscape
SynCore competes with global oncology biotech companies developing anti‑angiogenic agents and with ophthalmic device firms; its integrated therapeutic‑diagnostic approach and strategic partnerships aim to differentiate it.